Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorized
  2. c-icon icon-chevron-right
July 2, 2020

FDA may be risk-averse to grant emergency use for a Covid-19 vaccine; political pressure and hazy EUA standards are factors

By Victoria Smith

The FDA’s revocation of chloroquine and hydrochloroquine’s Emergency Use Authorization (EUA) after three months could mean the FDA may raise the bar for Covid-19 vaccines, requiring early protection data. Vaccines are sensitive to public scrutiny, specifically with limited data. However, the EUA is also sensitive to political pressure, even if it is designed to be evidence-based.

Nevertheless, manufacturing capabilities could also be a deciding criterion. This added factor could impact vaccines based on new technologies or developers with less production experience. Read more here.

Related Companies

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU